Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.55 |
| ▸ | CDK4 | P11802 | 3/20 | 0.39 |
| ▸ | CCND1 | P24385 | 3/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | MPL | P40238 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13284303 | 0.87 | NR1H4 (0.58) | NR1H4CDK4CCND1ABCB1ABCG2 | |
| SCHEMBL274752 | 0.86 | NR1H4 (0.77) | NR1H4 | |
| SCHEMBL5731733 | 0.86 | NR1H4 (0.55) | NR1H4CDK4CCND1ABCB1ABCG2 | |
| SCHEMBL273500 | 0.85 | NR1H4 (0.73) | NR1H4CDK4CCND1ABCB1ABCG2 | |
| SCHEMBL29881430 | 0.85 | NR1H4 (0.73) | NR1H4CDK4CCND1ABCB1ABCG2 | |
| SCHEMBL5732378 | 0.83 | NR1H4 (0.56) | NR1H4CDK4CCND1 | |
| SCHEMBL5731825 | 0.80 | NR1H4 (0.49) | NR1H4CDK4CCND1MPLKDM4E | |
| Cyclopentanamine SCHEMBL1460097 | 0.78 | NR1H4 (0.63) | NR1H4CDK4CCND1ABCB1ABCG2 | |
| SCHEMBL5732216 | 0.77 | NR1H4 (0.49) | NR1H4CDK4CCND1ABCB1ABCG2 | |
| SCHEMBL273830 | 0.77 | NR1H4 (0.78) | NR1H4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133992-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | X-CEPTOR THERAPEUTICS INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | HTR5A, MTNR1A, PTGDR | NR1H4 268/4885CDK4 1220/4885CCND1 3537/4885 |
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | HTR5A, MTNR1A, PTGDR | NR1H4 268/4885CDK4 1220/4885CCND1 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.